INVA Stock - Innoviva, Inc.
Unlock GoAI Insights for INVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $358.71M | $310.46M | $331.34M | $391.87M | $336.79M |
| Gross Profit | $322.11M | $267.82M | $317.55M | $391.87M | $336.79M |
| Gross Margin | 89.8% | 86.3% | 95.8% | 100.0% | 100.0% |
| Operating Income | $166.87M | $113.89M | $-36,946,000 | $375.10M | $321.12M |
| Net Income | $23.39M | $179.72M | $213.92M | $265.85M | $224.40M |
| Net Margin | 6.5% | 57.9% | 64.6% | 67.8% | 66.6% |
| EPS | $0.37 | $2.92 | $3.07 | $3.24 | $2.21 |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Visit WebsiteEarnings History & Surprises
INVAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.34 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.46 | $1.08 | +134.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.57 | $0.77 | +35.1% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.29 | $0.25 | -13.8% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $0.34 | $0.57 | +67.6% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.27 | $0.02 | -92.6% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $0.24 | $0.68 | +183.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.17 | $0.46 | +170.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.23 | $0.76 | +230.4% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.27 | $0.98 | +263.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.26 | $0.08 | -69.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.23 | $0.42 | +82.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.41 | $0.25 | -39.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $2.75 | $0.60 | -78.2% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $0.55 | $0.05 | -90.9% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $0.40 | $0.42 | +5.0% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $0.41 | $0.55 | +34.1% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.43 | $0.90 | +109.3% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.29 | $0.90 | +210.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about INVA
What is INVA's current stock price?
What is the analyst price target for INVA?
What sector is Innoviva, Inc. in?
What is INVA's market cap?
Does INVA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INVA for comparison